Zoetis Inc. $ZTS Shares Sold by Lansing Management LP

Lansing Management LP cut its holdings in Zoetis Inc. (NYSE:ZTS) by 62.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,555 shares of the company’s stock after selling 21,116 shares during the period. Zoetis makes up 1.3% of Lansing Management LP’s investment portfolio, making the stock its 8th biggest holding. Lansing Management LP’s holdings in Zoetis were worth $1,837,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the stock. Lido Advisors LLC raised its holdings in Zoetis by 25.2% during the third quarter. Lido Advisors LLC now owns 47,420 shares of the company’s stock valued at $6,940,000 after buying an additional 9,531 shares in the last quarter. Gotham Asset Management LLC boosted its stake in shares of Zoetis by 33.0% during the 3rd quarter. Gotham Asset Management LLC now owns 74,801 shares of the company’s stock worth $10,945,000 after acquiring an additional 18,574 shares in the last quarter. Delta Global Management LP boosted its stake in shares of Zoetis by 83.1% during the 3rd quarter. Delta Global Management LP now owns 16,151 shares of the company’s stock worth $2,363,000 after acquiring an additional 7,331 shares in the last quarter. Destination Wealth Management increased its holdings in shares of Zoetis by 2.9% during the 3rd quarter. Destination Wealth Management now owns 135,612 shares of the company’s stock valued at $19,843,000 after acquiring an additional 3,807 shares during the last quarter. Finally, Element Capital Management LLC acquired a new position in shares of Zoetis during the 3rd quarter valued at about $511,000. 92.80% of the stock is currently owned by institutional investors.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $118.20 on Tuesday. The business has a 50 day moving average price of $125.12 and a 200 day moving average price of $131.33. Zoetis Inc. has a twelve month low of $114.47 and a twelve month high of $172.23. The company has a market cap of $49.90 billion, a price-to-earnings ratio of 19.63, a PEG ratio of 1.76 and a beta of 0.95. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The firm had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. During the same quarter last year, the firm posted $1.40 EPS. The company’s revenue was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be given a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a yield of 1.8%. Zoetis’s payout ratio is 35.22%.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on ZTS shares. William Blair restated an “outperform” rating on shares of Zoetis in a report on Monday, March 2nd. Wall Street Zen upgraded Zoetis from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Leerink Partners reissued a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. Stifel Nicolaus reduced their price objective on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a research note on Tuesday, November 18th. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $135.00 price objective (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. Six analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Zoetis presently has a consensus rating of “Hold” and an average target price of $152.91.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.